Research programme: mitochondrial-based therapeutics - PAEAN Biotechnology
Alternative Names: PN-RSLatest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator PAEAN Biotechnology
- Class Cell therapies
- Mechanism of Action Mitochondria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders; Hearing loss; Parkinson's disease
Most Recent Events
- 08 Apr 2024 Preclinical trials in Eye disorders in South Korea (Parenteral), prior to July 2024 (PAEAN Biotechnology pipeline, July 2024)
- 08 Apr 2024 Preclinical trials in Hearing loss in South Korea (Parenteral), prior to July 2024 (PAEAN Biotechnology pipeline, July 2024)
- 08 Apr 2024 Preclinical trials in Parkinson's disease in South Korea (Parenteral), prior to July 2024 (PAEAN Biotechnology pipeline, July 2024)